Viaject
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7667 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 8 | 4 | 21 | 3 | 11 | 46 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 9 | 3 | 20 | 3 | 11 | 46 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | — | — | 4 | 2 | 7 |
| Hepatitis c | D006526 | — | B19.2 | — | — | — | 4 | 1 | 5 |
| Hepatitis | D006505 | — | K75.9 | — | — | — | 4 | 1 | 5 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | 4 | 1 | 5 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | — | — | 2 | 1 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | — | — | 1 | — | 3 |
| Hyperglycemia | D006943 | — | R73.9 | 1 | — | — | 2 | — | 3 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 2 | 1 | 3 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 4 | — | 1 | — | — | 5 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | 1 | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | 2 | 3 |
| Hypoglycemia | D007003 | — | E16.2 | 1 | 1 | — | — | 1 | 3 |
| Gestational diabetes | D016640 | — | O24.4 | — | 1 | — | — | — | 1 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | 1 | 5 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 1 | 2 |
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypercholesterolemia | D006937 | — | — | — | — | — | — | 2 | 2 |
| Hepacivirus | D016174 | — | — | — | — | — | — | 1 | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 1 | 1 |
| Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 1 | 1 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | — |
| INN | — |
| Description | — |
| Classification | Unknown |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | — |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | — |
Target
No data
Variants
No data
Financial
No data
Trends
No data
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use